F 262 Revue Neurologique FMC

Somnolence et syndromes parkinsoniens

locomotor activity and striatal dopamine release in rats. Eur

Neuropsychopharmacol, 8:113-120.

Merino-Andreu M, Arnulf I, Konofal E, Derenne JP, Agid

Y. (2003). Unawareness of naps in Parkinson’s disease and

in disorders with excessive daytime sleepiness. Neurology,

60:1553-1554.

Monaca C, Laloux C, Jacquesson JM, et al. (2004). Vigilance

states in a parkinsonian model, the MPTP mouse. Eur J Neurosci,

20:2474-2478.

Monaca C, Duhamel A, Jacquesson JM, et al. (2006).

Vigilance troubles in Parkinson’s disease: A subjective and

objective polysomnographic study. Sleep Med, 7:448-453.

Olanow CW, Schapira AH, Roth T. (2000). Waking up to sleep

episodes in Parkinson’s disease. Mov disord, 15:212-215.

Ondo WG, Vuong KD, Khan H, Atassi F, Kwak C, Jankovic

J. (2001). Daytime sleepiness and other sleep disorders in

Parkinson’s disease. Neurology, 57:1392-1396.

Ondo WG, Fayle R, Atassi F, Jankovic J. (2005). Modafinil

for daytime somnolence in Parkinson’s disease: double blind,

placebo controlled parallel trial. JNNP, 76:1636-1639.

Overeem S, van Hilten J, Ripley B, Mignot E, Nishino S,

Lammers G. (2002). Normal hypocretin-1 levels in Parkinson’s

disease patients with excessive daytime sleepiness. Neurology,

58:498-499.

Paus S, Seeger G, Brecht H, et al. (2004). Association study

of dopamine D2, D3, D4 receptor and serotonin transporter gene

polymorphisms with sleep attacks in Parkinson’s disease. Mov

Disord, 19:705-707.

Razmy A, Lang AE, Shapiro CM. (2004). Predictors of

impaired daytime sleep and wakefulness in patients with

Parkinson’s disease treated with older (ergot) vs. newer (non-

ergot) dopamine agonist. Arch Neurol, 61:97-102.

Roche S, Jacquesson JM, Destee A, Defebvre L,

Derambure P, Monaca C. (2007). Sleep and vigilance in cor-

ticobasal degeneration: a descriptive study. Neurophysiol

Clin, 37:261-264.

Roth T, Rye D, Borchert L, Bartlett C, et al. (2003).

Assessment of sleepiness and unintended sleep in Parkinson’s

disease patients taking dopamine agonists. Sleep Med, 4:275-

280.

Rye D, Bliwise DL, Dihenia B, Gurecki P. (2000). Daytime

sleepiness in Parkinson’s disease. J Sleep Res, 9:63-69.

Sanjiv CC, Schulzer M, Mak E, et al. (2001). Daytime som-

nolence in patients with Parkinson’s disease. Parkinsonism Relat

Disord, 7:283-286.

Seppi K, Hogl B, Diem A, Peralta C, Wenning GK, Poewe

W. (2006). Levodopa-induced sleepiness in the Parkinson variant

of multiple system atrophy. Mov disord, 21:1281-1283.

Tan EK, Lum SY, Fook-Chong SM, et al. (2002). Evaluation

of somnolence in Parkinson’s disease: comparison with age and

sex-matched controls. Neurology, 58:465-468.

Thannickal TC, Lai YY, Siegel JM. (2007). Hypocretin

(orexin) cell loss in Parkinson’s disease. Brain, 130:

1586-1595.

Tracik F, Ebersbach G. (2001). Sudden daytime sleep

onset in Parkinson’s disease: polysomnographic recordings.

Mov Disord, 16:500-506.

Trampus M, Ferri N, Adami M, Ongini E. (1993). The

dopamine D1 receptor agonists, A68930 and SKF 38393, induce

arousals and suppress REM sleep in the rat. Eur J Pharmacol,

22:83-87.

Ulivelli M, Rossi S, Lombardi C, et al. (2002).

Polysomnographic characterization of pergolide-induced sleep

attacks in idiopathic PD. Neurology, 58:462-465.

Wetter TC, Collado-Seidel V, Pollmächer T, Yassouridis A,

Trenkwalder C. (2000). Sleep and periodic leg movement pat-

terns in drug-free patients with Parkinson’s disease and multiple

system atrophy. Sleep, 23:361-367.

ERRATUM

Les affiliations des auteurs de l’article « Intérêt de la spectroscopie par résonance magnétique du proton en pathologie tumorale cérébrale » paru dans le hors-série de la Revue neurologique du mois de septembre, ont été inversées.

Il fallait lire :(2) Laboratoire d’imagerie fonctionnelle, INSERM U678, Université Pierre et Marie Curie, Paris.(3) Service de neuro-oncologie, Groupe Hospitalier Pitié-Salpétrière, Paris.

Nous prions les lecteurs de la revue ainsi que les auteurs de bien vouloir nous en excuser.